Core Laboratories Inc Stock Price, News & Analysis

Core Laboratories reported a Q3 2022 revenue of $126 million, a 4% sequential increase and 7% year-over-year. Operating income rose by over 25% sequentially. The company's GAAP EPS stood at $0.16, while ex-items EPS was $0.18. Free cash flow reached $3.1 million. Despite currency devaluation impacts, revenues would be higher at constant exchange rates. Core continues to focus on maximizing free cash flow and maintaining a $0.01$126-131 million in revenue.

Core Laboratories (NYSE: CLB) will host its third quarter 2022 conference call on October 27, 2022, at 7:30 a.m. CDT (2:30 p.m. CEST). The call will cover financial and operational results, featuring Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham. An earnings press release will precede the call, released after market close on October 26. Investors can access the call via webcast at www.corelab.com, with a replay available for 10 days. Core Labs specializes in optimizing petroleum reservoir performance.

Core Laboratories N.V. (CLB) reported Q2 2022 revenue of $120.9 million, marking a 5% sequential increase and a 2% year-over-year growth. Despite the geopolitical impact of the Russia-Ukraine conflict, the company achieved an operating income of $11.7 million and a GAAP EPS of $0.15. Core extended its revolving credit facility through 2026 and announced a $0.01 quarterly dividend. Looking ahead, Q3 revenue is projected to range from $123 million to $129 million, with EPS anticipated between $0.13 and $0.18.

Core Laboratories (CLB) will host its second quarter 2022 conference call on July 28, 2022, at 7:30 a.m. CDT. Key executives including Chairman and CEO Larry Bruno, CFO Chris Hill, and SVP Gwen Gresham will discuss financial and operational outcomes, with an earnings press release available after market close on July 27. The call can be accessed live via the company's website or through a telephone dial-in option by contacting Lena Brennan. Core Laboratories specializes in optimizing petroleum reservoir performance with over 70 offices globally.

Core Laboratories N.V. (NYSE: CLB) has announced the launch of an at-the-market equity offering program allowing the sale of up to $60 million in common shares. The company has partnered with Wells Fargo Securities and BofA Securities as sales agents. The funds will be utilized for general corporate purposes, including product development, capital expenditures, and potential acquisitions. The offering is structured under the existing shelf registration with the SEC. Core Labs retains the right to suspend or terminate the program as needed.

Core Laboratories N.V. (CLB) reported Q1 2022 revenue of $115.3 million, a 6% increase year-over-year. The company faced an operating loss of $400,000 and a GAAP EPS of $(0.04), while ex-items EPS was $0.08. Challenges included COVID-19 impacts and the Russia-Ukraine conflict, which disrupted service revenue. A new CCS strategic alliance with Talos Energy was launched, focusing on carbon emission reduction. The company reduced net debt by $3.3 million and announced a quarterly dividend of $0.01 per share, payable in Q2 2022.

Core Laboratories N.V. (CLB) and Talos Energy Inc. (TALO) have formed a strategic alliance focused on carbon capture and sequestration (CCS) technologies. This collaboration aims to leverage Core Lab's reservoir optimization expertise and Talos's subsurface characterization skills to evaluate CCS sites effectively. The companies will utilize advanced reservoir characterization techniques, promoting transparency in CO₂ monitoring. Talos is also a member of Core Lab's CCS consortium to address challenges in subsurface CO₂ storage. Their combined efforts are positioned to enhance CCS solutions and contribute to climate initiatives.

Core Laboratories N.V. (NYSE: CLB) has revised its Q1 2022 revenue guidance to between $110 million and $113 million due to significant disruptions from the Omicron variant and the ongoing Russia-Ukraine conflict. Approximately 15% of employees were affected by COVID-19, causing operational delays. Despite these challenges, the company remains positive about its 2022 outlook. Additionally, Core launched a Carbon Capture and Sequestration Consortium to address technical risks in subsurface carbon sequestration, collaborating with industry leaders.

Core Laboratories N.V. (CLB) reported Q4 2021 revenues of $125.1M, with an operating income of $14.2M and EPS of $0.06. The company saw a 14% year-over-year growth in international revenue. Despite challenges from COVID-19, especially in the Middle East, projects are underway, including a large reservoir evaluation. Revenue from Production Enhancement rose 15% sequentially. The Board approved a quarterly cash dividend of $0.01 per share, payable on March 7, 2022. For Q1 2022, Core expects revenue between $117M and $122M.